Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2018 | 12-2017 | 12-2016 | 12-2006 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 28,909 | 50,573 | 51,737 | N/A |
| Receivables | N/A | N/A | 1,294 | N/A |
| Other current assets | 184 | 72 | 90 | 0 |
| TOTAL | $29,093 | $50,645 | $53,121 | $N/A |
| Non-Current Assets | ||||
| PPE Net | 288 | 444 | 384 | N/A |
| Investments And Advances | 247 | 0 | 0 | 0 |
| Intangibles | 23,081 | 84 | 84 | 0 |
| Other Non-Current Assets | 172 | 161 | 125 | 0 |
| TOTAL | $23,788 | $689 | $593 | $N/A |
| Total Assets | $52,881 | $51,334 | $53,714 | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 7,998 | 5,979 | 3,804 | 0 |
| TOTAL | $7,998 | $5,979 | $3,804 | $N/A |
| Non-Current Liabilities | ||||
| Long Term Debt | 13,975 | 9,680 | 8,336 | N/A |
| Other Non-Current Liabilities | 290 | 162 | 0 | 0 |
| TOTAL | $14,264 | $9,842 | $8,336 | $N/A |
| Total Liabilities | $22,263 | $15,820 | $12,139 | $N/A |
| Shareholders' Equity | ||||
| Common Shares | 51,627 | 41,514 | 36,710 | N/A |
| Retained earnings | -132,469 | -90,283 | -50,391 | N/A |
| TOTAL | $30,618 | $35,513 | $41,575 | $N/A |
| Total Liabilities And Equity | $52,881 | $51,334 | $53,714 | $0 |